Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13160877 | 0.89 | ALDH1A1 (0.56) | TP53AKR1C3GAARAB9ANPC1 | |
| SCHEMBL7270788 | 0.86 | CES2 (0.53) | TP53POLBRAB9ANPC1LMNA | |
| SCHEMBL257273 | 0.86 | TP53 (0.60) | TP53AKR1C3POLBNPSR1GAA | |
| SCHEMBL13160885 | 0.84 | MAPK1 (0.48) | TP53AKR1C3POLBRAB9ANPC1 | |
| SCHEMBL28384878 | 0.83 | AKR1C3 (0.61) | TP53AKR1C3POLBNPSR1GAA | |
| SCHEMBL18196076 | 0.83 | LMNA (0.50) | TP53RAB9ANPC1LMNAKMT2A | |
| SCHEMBL230930 | 0.81 | ALDH1A1 (0.63) | TP53NPSR1RAB9ANPC1LMNA | |
| SCHEMBL305558 | 0.81 | NPSR1 (0.60) | TP53AKR1C3POLBNPSR1GAA | |
| SCHEMBL29612638 | 0.81 | ALDH1A1 (0.63) | TP53NPSR1RAB9ANPC1LMNA | |
| SCHEMBL29356028 | 0.81 | NPSR1 (0.60) | TP53AKR1C3POLBNPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008922-A1 | BRANCHED CHAIN-CONTAINING AROMATIC COMPOUND | AJINOMOTO CO., INC. (JP) | 2017-01-12 | — | — | US | disclosed |
| US-9499579-B2 | Branched chain-containing aromatic compound | AJINOMOTO CO., INC. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-8546534-B2 | Branched chain-containing aromatic compound | AJINOMOTO CO., INC. (JP) | 2013-10-01 | — | — | US | disclosed |
| US-20120059149-A1 | BRANCHED CHAIN-CONTAINING AROMATIC COMPOUND | AJINOMOTO CO. INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7189718-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059149-A1 | BRANCHED CHAIN-CONTAINING AROMATIC COMPOUND | VIP, BCAT2, IAPP | TP53 1974/4885AKR1C3 698/4885POLB 3764/4885 |
| US-20170008922-A1 | BRANCHED CHAIN-CONTAINING AROMATIC COMPOUND | VIP, IAPP, BCAT1 | TP53 1648/4885AKR1C3 409/4885POLB 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.